Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli

Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli strains resistant to aztreonam-avibactam have emerged but resistance mechanisms remain to be elucidated. We performed a study to investigate the...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 13; p. 1047109
Main Authors Ma, Ke, Zong, Zhiyong
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 04.11.2022
Subjects
Online AccessGet full text
ISSN1664-302X
1664-302X
DOI10.3389/fmicb.2022.1047109

Cover

Loading…
Abstract Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli strains resistant to aztreonam-avibactam have emerged but resistance mechanisms remain to be elucidated. We performed a study to investigate the mechanism for aztreonam-avibactam in a carbapenem-resistant Escherichia coli clinical strain. This strain was resistant to aztreonam-avibactam (aztreonam MIC, 16 mg/L in the presence of 4 mg/L avibactam). Whole genome sequencing revealed that the strain carried metallo-β-lactamase gene bla NDM-4 and the extended-spectrum β-lactamase (ESBL) gene bla CTX-M-15 and had a YRIK four amino acid insertion in penicillin-binding protein 3 (PBP3). bla CTX-M-15 was cloned into pET-28a(+), followed by the transformation, with the gene, of E. coli strain 035125∆pCMY42 possessing the YRIK insertion in PBP3 and strain BL21 with the wildtype PBP3. bla CTX-M-14 , another common ESBL gene, and bla CTX-M-199 , a hybrid of bla CTX-M-14 and bla CTX-M-15 were also individually cloned into both E. coli strains for comparison. Aztreonam-avibactam resistance was only observed in the E. coli strains with the YRIK insertion in PBP3 that produced CTX-M-15 or its hybrid enzyme CTX-M-199. Checkerboard titration assays were performed to determine the synergistic effects between aztreonam-avibactam and ceftazidime or meropenem. Doubling avibactam concentration in vitro reversed aztreonam-avibactam resistance, while the combination of aztreonam-avibactam and ceftazidime or meropenem did not. In conclusion, CTX-M enzymes with activity against aztreonam, (e.g., CTX-M-15 and CTX-M-199), can confer resistance in the combination of PBP3 with YRIK insertions in metallo-β-lactamase-producing carbapenem-resistant E. coli . Doubling the concentration of avibactam may overcome such resistance.
AbstractList Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli strains resistant to aztreonam-avibactam have emerged but resistance mechanisms remain to be elucidated. We performed a study to investigate the mechanism for aztreonam-avibactam in a carbapenem-resistant Escherichia coli clinical strain. This strain was resistant to aztreonam-avibactam (aztreonam MIC, 16 mg/L in the presence of 4 mg/L avibactam). Whole genome sequencing revealed that the strain carried metallo-β-lactamase gene bla NDM-4 and the extended-spectrum β-lactamase (ESBL) gene bla CTX-M-15 and had a YRIK four amino acid insertion in penicillin-binding protein 3 (PBP3). bla CTX-M-15 was cloned into pET-28a(+), followed by the transformation, with the gene, of E. coli strain 035125∆pCMY42 possessing the YRIK insertion in PBP3 and strain BL21 with the wildtype PBP3. bla CTX-M-14, another common ESBL gene, and bla CTX-M-199, a hybrid of bla CTX-M-14 and bla CTX-M-15 were also individually cloned into both E. coli strains for comparison. Aztreonam-avibactam resistance was only observed in the E. coli strains with the YRIK insertion in PBP3 that produced CTX-M-15 or its hybrid enzyme CTX-M-199. Checkerboard titration assays were performed to determine the synergistic effects between aztreonam-avibactam and ceftazidime or meropenem. Doubling avibactam concentration in vitro reversed aztreonam-avibactam resistance, while the combination of aztreonam-avibactam and ceftazidime or meropenem did not. In conclusion, CTX-M enzymes with activity against aztreonam, (e.g., CTX-M-15 and CTX-M-199), can confer resistance in the combination of PBP3 with YRIK insertions in metallo-β-lactamase-producing carbapenem-resistant E. coli. Doubling the concentration of avibactam may overcome such resistance.Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli strains resistant to aztreonam-avibactam have emerged but resistance mechanisms remain to be elucidated. We performed a study to investigate the mechanism for aztreonam-avibactam in a carbapenem-resistant Escherichia coli clinical strain. This strain was resistant to aztreonam-avibactam (aztreonam MIC, 16 mg/L in the presence of 4 mg/L avibactam). Whole genome sequencing revealed that the strain carried metallo-β-lactamase gene bla NDM-4 and the extended-spectrum β-lactamase (ESBL) gene bla CTX-M-15 and had a YRIK four amino acid insertion in penicillin-binding protein 3 (PBP3). bla CTX-M-15 was cloned into pET-28a(+), followed by the transformation, with the gene, of E. coli strain 035125∆pCMY42 possessing the YRIK insertion in PBP3 and strain BL21 with the wildtype PBP3. bla CTX-M-14, another common ESBL gene, and bla CTX-M-199, a hybrid of bla CTX-M-14 and bla CTX-M-15 were also individually cloned into both E. coli strains for comparison. Aztreonam-avibactam resistance was only observed in the E. coli strains with the YRIK insertion in PBP3 that produced CTX-M-15 or its hybrid enzyme CTX-M-199. Checkerboard titration assays were performed to determine the synergistic effects between aztreonam-avibactam and ceftazidime or meropenem. Doubling avibactam concentration in vitro reversed aztreonam-avibactam resistance, while the combination of aztreonam-avibactam and ceftazidime or meropenem did not. In conclusion, CTX-M enzymes with activity against aztreonam, (e.g., CTX-M-15 and CTX-M-199), can confer resistance in the combination of PBP3 with YRIK insertions in metallo-β-lactamase-producing carbapenem-resistant E. coli. Doubling the concentration of avibactam may overcome such resistance.
Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli strains resistant to aztreonam-avibactam have emerged but resistance mechanisms remain to be elucidated. We performed a study to investigate the mechanism for aztreonam-avibactam in a carbapenem-resistant Escherichia coli clinical strain. This strain was resistant to aztreonam-avibactam (aztreonam MIC, 16 mg/L in the presence of 4 mg/L avibactam). Whole genome sequencing revealed that the strain carried metallo-β-lactamase gene blaNDM-4 and the extended-spectrum β-lactamase (ESBL) gene blaCTX-M-15 and had a YRIK four amino acid insertion in penicillin-binding protein 3 (PBP3). blaCTX-M-15 was cloned into pET-28a(+), followed by the transformation, with the gene, of E. coli strain 035125∆pCMY42 possessing the YRIK insertion in PBP3 and strain BL21 with the wildtype PBP3. blaCTX-M-14, another common ESBL gene, and blaCTX-M-199, a hybrid of blaCTX-M-14 and blaCTX-M-15 were also individually cloned into both E. coli strains for comparison. Aztreonam-avibactam resistance was only observed in the E. coli strains with the YRIK insertion in PBP3 that produced CTX-M-15 or its hybrid enzyme CTX-M-199. Checkerboard titration assays were performed to determine the synergistic effects between aztreonam-avibactam and ceftazidime or meropenem. Doubling avibactam concentration in vitro reversed aztreonam-avibactam resistance, while the combination of aztreonam-avibactam and ceftazidime or meropenem did not. In conclusion, CTX-M enzymes with activity against aztreonam, (e.g., CTX-M-15 and CTX-M-199), can confer resistance in the combination of PBP3 with YRIK insertions in metallo-β-lactamase-producing carbapenem-resistant E. coli. Doubling the concentration of avibactam may overcome such resistance.
Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli strains resistant to aztreonam-avibactam have emerged but resistance mechanisms remain to be elucidated. We performed a study to investigate the mechanism for aztreonam-avibactam in a carbapenem-resistant Escherichia coli clinical strain. This strain was resistant to aztreonam-avibactam (aztreonam MIC, 16 mg/L in the presence of 4 mg/L avibactam). Whole genome sequencing revealed that the strain carried metallo-β-lactamase gene bla NDM-4 and the extended-spectrum β-lactamase (ESBL) gene bla CTX-M-15 and had a YRIK four amino acid insertion in penicillin-binding protein 3 (PBP3). bla CTX-M-15 was cloned into pET-28a(+), followed by the transformation, with the gene, of E. coli strain 035125∆pCMY42 possessing the YRIK insertion in PBP3 and strain BL21 with the wildtype PBP3. bla CTX-M-14 , another common ESBL gene, and bla CTX-M-199 , a hybrid of bla CTX-M-14 and bla CTX-M-15 were also individually cloned into both E. coli strains for comparison. Aztreonam-avibactam resistance was only observed in the E. coli strains with the YRIK insertion in PBP3 that produced CTX-M-15 or its hybrid enzyme CTX-M-199. Checkerboard titration assays were performed to determine the synergistic effects between aztreonam-avibactam and ceftazidime or meropenem. Doubling avibactam concentration in vitro reversed aztreonam-avibactam resistance, while the combination of aztreonam-avibactam and ceftazidime or meropenem did not. In conclusion, CTX-M enzymes with activity against aztreonam, (e.g., CTX-M-15 and CTX-M-199), can confer resistance in the combination of PBP3 with YRIK insertions in metallo-β-lactamase-producing carbapenem-resistant E. coli . Doubling the concentration of avibactam may overcome such resistance.
Author Ma, Ke
Zong, Zhiyong
AuthorAffiliation 1 Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China
2 Center for Pathogen Research, West China Hospital, Sichuan University , Chengdu , China
3 Division of Infectious Diseases, State Key Laboratory of Biotherapy , Chengdu , China
AuthorAffiliation_xml – name: 1 Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China
– name: 3 Division of Infectious Diseases, State Key Laboratory of Biotherapy , Chengdu , China
– name: 2 Center for Pathogen Research, West China Hospital, Sichuan University , Chengdu , China
Author_xml – sequence: 1
  givenname: Ke
  surname: Ma
  fullname: Ma, Ke
– sequence: 2
  givenname: Zhiyong
  surname: Zong
  fullname: Zong, Zhiyong
BookMark eNp9ks1u1DAUhSNUJErpC7Dykk0Gx3HiZIOERgUqFSGhInVnXTs3M7dK7MH2lJ9n4KFxZkaIssAL2_K557u2fJ4XZ847LIqXFV_Vdde_HmeyZiW4EKuKS1Xx_klxXrWtLGsu7s7-2j8rLmO853lILvJ8Xvz6jJFiAmeRJc_gZwroHcwlPJABm2Bmw_4grW_vyo9l1TByLG2R7QJGXGx-ZDt0ZGmayJWG3EBuk2WfMJfW7BulLcPvKQCDmVxuYmmIC-Yq2i0GslsCZv1EL4qnI0wRL0_rRfHl3dXt-kN58-n99frtTWmlbFLZDj2YQQIX2DTN2LTKCNOLusfWIHJlZGVEZ0Ap6HhlAbDpsRG2aoGbWpr6org-cgcP93oXaIbwQ3sgfTjwYaMhJLITam64bQ03puuMlCC6vu8GhcoMzSBaLjPrzZG125sZB4suP3R6BH2sONrqjX_QfatkzVUGvDoBgv-6x5j0TNHiNIFDv49aqLqTvcrfm0vFsdQGH2PA8U-biuslCvoQBb1EQZ-ikE3dPyZLCRL55To0_c_6Gx6yvug
CitedBy_id crossref_primary_10_1089_mdr_2024_0150
crossref_primary_10_1016_j_micpath_2024_106668
crossref_primary_10_1128_aac_01548_23
crossref_primary_10_1093_jac_dkad249
crossref_primary_10_1128_spectrum_00953_24
crossref_primary_10_3390_antibiotics13080766
crossref_primary_10_1016_j_ijantimicag_2023_106985
Cites_doi 10.1074/jbc.271.37.22538
10.1038/s41598-017-18910-w
10.1093/jac/dku568
10.1128/AAC.05961-11
10.1093/cid/ciaa1478
10.1016/j.ijantimicag.2022.106642
10.1128/AAC.01659-20
10.1093/jac/dkx146
10.3389/fmicb.2021.616687
10.1128/AAC.45.8.2269-2275.2001
10.1093/jac/dkf240
10.1128/AAC.03057-14
10.1016/j.diagmicrobio.2017.05.009
10.1089/mdr.2010.0137
10.1073/pnas.1205073109
10.1016/j.cmi.2021.11.025
10.1093/cid/ciy660
10.1128/CMR.00115-18
10.1128/AAC.01658-07
10.1038/s41467-020-15666-2
10.1046/j.1469-0691.2000.00149.x
10.1128/AAC.46.2.534-537.2002
10.1093/jac/dkab279
10.1021/bi501547k
10.1128/AAC.48.6.2308-2313.2004
10.1128/AAC.46.6.1985-1988.2002
10.1016/j.ijantimicag.2006.09.005
10.1128/mSystems.00821-20
10.1016/j.ebiom.2017.04.032
10.1093/jac/dkg256
10.1128/AAC.00389-17
10.1128/spectrum.02670-21
10.1128/AAC.44.11.3061-3068.2000
10.1128/AAC.00756-10
10.1128/AAC.00562-17
10.1016/j.tim.2011.09.005
10.1093/jac/dkn339
10.1371/journal.pone.0056926
10.1128/AAC.00774-09
ContentType Journal Article
Copyright Copyright © 2022 Ma and Zong.
Copyright © 2022 Ma and Zong. 2022 Ma and Zong
Copyright_xml – notice: Copyright © 2022 Ma and Zong.
– notice: Copyright © 2022 Ma and Zong. 2022 Ma and Zong
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fmicb.2022.1047109
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-302X
ExternalDocumentID oai_doaj_org_article_0b0c6b0bb88b44a28998d7e7bd5d2604
PMC9674307
10_3389_fmicb_2022_1047109
GrantInformation_xml – fundername: ;
  grantid: 82172309; 81861138055
– fundername: West China Hospital of Sichuan University
  grantid: ZYYC08006; ZYGD22001
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
ECGQY
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c445t-6d9abd4a02e555f567b2b9239e6bee07b41b28ba77a801caae59e52c16a0b34b3
IEDL.DBID DOA
ISSN 1664-302X
IngestDate Wed Aug 27 01:24:25 EDT 2025
Thu Aug 21 18:39:55 EDT 2025
Fri Jul 11 14:10:15 EDT 2025
Tue Jul 01 00:57:50 EDT 2025
Thu Apr 24 23:09:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c445t-6d9abd4a02e555f567b2b9239e6bee07b41b28ba77a801caae59e52c16a0b34b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Xian-Zhi Li, Health Canada, Canada
Reviewed by: Qi Wang, Peking University People's Hospital, China; Fabrice Compain, L'Institut Mutualiste Montsouris, France; Siqiang Niu, The First Affiliated Hospital of Chongqing Medical University, China
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
OpenAccessLink https://doaj.org/article/0b0c6b0bb88b44a28998d7e7bd5d2604
PQID 2738497202
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_0b0c6b0bb88b44a28998d7e7bd5d2604
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9674307
proquest_miscellaneous_2738497202
crossref_primary_10_3389_fmicb_2022_1047109
crossref_citationtrail_10_3389_fmicb_2022_1047109
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-11-04
PublicationDateYYYYMMDD 2022-11-04
PublicationDate_xml – month: 11
  year: 2022
  text: 2022-11-04
  day: 04
PublicationDecade 2020
PublicationTitle Frontiers in microbiology
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Lahiri (ref18) 2014; 58
Mendes (ref23) 2021; 76
Faheem (ref15) 2013; 8
Bonnet (ref4) 2003; 52
Bonnet (ref5) 2000; 44
Bonnet (ref3) 2001; 45
Paul (ref28) 2022; 28
Dutour (ref12) 2002; 46
Cantu (ref7) 1996; 271
Celenza (ref9) 2008; 62
Livermore (ref19) 2011; 55
Ehmann (ref13) 2012; 109
Nordmann (ref25) 2012; 56
Alm (ref1) 2015; 70
Wang (ref33) 2022; 10
Hentschke (ref16) 2011; 17
Wenzler (ref35) 2017; 88
Poirel (ref29) 2002; 50
(ref14) 2000; 6
Zhang (ref40) 2017; 19
Wang (ref34) 2018; 67
Wu (ref36) 2019; 32
Ma (ref20) 2020; 5
Tamma (ref32) 2021; 72
Chen (ref10) 2021; 12
Cai (ref6) 2017; 61
(ref11) 2022
Cartelle (ref8) 2004; 48
Mitchell (ref24) 2015; 54
Novais (ref27) 2008; 52
Zhang (ref38) 2018; 8
Yong (ref37) 2009; 53
Nordmann (ref26) 2011; 19
Zhang (ref39) 2017; 61
Ma (ref22) 2002; 46
Russ (ref30) 2020; 11
Bevan (ref2) 2017; 72
Sadek (ref31) 2020; 64
Ishii (ref17) 2007; 29
Ma (ref21) 2022; 60
References_xml – volume: 271
  start-page: 22538
  year: 1996
  ident: ref7
  article-title: Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 β-lactamase with altered substrate specificity for aztreonam and ceftazidime
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.271.37.22538
– volume: 8
  start-page: 390
  year: 2018
  ident: ref38
  article-title: Cryptic transmission of ST405 Escherichia coli carrying Bla NDM-4 in hospital
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-18910-w
– volume: 70
  start-page: 1420
  year: 2015
  ident: ref1
  article-title: Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3
  publication-title: J. Antimicrob. Chemother.
  doi: 10.1093/jac/dku568
– volume: 56
  start-page: 2184
  year: 2012
  ident: ref25
  article-title: NDM-4 metallo-β-lactamase with increased carbapenemase activity from Escherichia coli
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.05961-11
– volume: 72
  start-page: e169
  year: 2021
  ident: ref32
  article-title: Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciaa1478
– volume: 60
  start-page: 106642
  year: 2022
  ident: ref21
  article-title: Aztreonam-avibactam may not replace ceftazidime/avibactam: the case of KPC-21 carbapenemase and penicillin-binding protein 3 with four extra amino acids
  publication-title: Int. J. Antimicrob. Agents
  doi: 10.1016/j.ijantimicag.2022.106642
– volume: 64
  start-page: 01659
  year: 2020
  ident: ref31
  article-title: Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-β-lactamase-producing Escherichia coli isolates
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01659-20
– volume: 72
  start-page: 2145
  year: 2017
  ident: ref2
  article-title: Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype
  publication-title: J. Antimicrob. Chemother.
  doi: 10.1093/jac/dkx146
– volume: 12
  start-page: 616687
  year: 2021
  ident: ref10
  article-title: Fecal carriage and genetic characterization of CTX-M-1/9/1-producing Escherichia coli from healthy humans in Hangzhou, China
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2021.616687
– volume: 45
  start-page: 2269
  year: 2001
  ident: ref3
  article-title: Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.45.8.2269-2275.2001
– volume: 50
  start-page: 1031
  year: 2002
  ident: ref29
  article-title: Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3
  publication-title: J. Antimicrob. Chemother.
  doi: 10.1093/jac/dkf240
– volume: 58
  start-page: 5704
  year: 2014
  ident: ref18
  article-title: Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.03057-14
– volume: 88
  start-page: 352
  year: 2017
  ident: ref35
  article-title: Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2017.05.009
– volume: 17
  start-page: 165
  year: 2011
  ident: ref16
  article-title: CMY-42, a novel plasmid-mediated CMY-2 variant AmpC β-lactamase
  publication-title: Microb. Drug Resist.
  doi: 10.1089/mdr.2010.0137
– volume: 109
  start-page: 11663
  year: 2012
  ident: ref13
  article-title: Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1205073109
– volume: 28
  start-page: 521
  year: 2022
  ident: ref28
  article-title: European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)
  publication-title: Clin. Microbiol. Infect.
  doi: 10.1016/j.cmi.2021.11.025
– volume: 67
  start-page: S196
  year: 2018
  ident: ref34
  article-title: Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012-2016)
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciy660
– volume: 32
  start-page: e00115
  year: 2019
  ident: ref36
  article-title: NDM metallo-β-lactamases and their bacterial producers in health care settings
  publication-title: Clin. Microbiol. Rev.
  doi: 10.1128/CMR.00115-18
– volume: 52
  start-page: 2377
  year: 2008
  ident: ref27
  article-title: Mutational events in cefotaximase extended-spectrum β-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01658-07
– volume: 11
  start-page: 2029
  year: 2020
  ident: ref30
  article-title: Escape mutations circumvent a tradeoff between resistance to a β-lactam and resistance to a β-lactamase inhibitor
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-15666-2
– volume: 6
  start-page: 503
  year: 2000
  ident: ref14
  article-title: EUCAST definitive document e.Def 1.2, may 2000: terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents
  publication-title: Clin. Microbiol. Infect.
  doi: 10.1046/j.1469-0691.2000.00149.x
– volume: 46
  start-page: 534
  year: 2002
  ident: ref12
  article-title: CTX-M-1, CTX-M-3, and CTX-M-14 β-lactamases from Enterobacteriaceae isolated in France
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.46.2.534-537.2002
– volume: 76
  start-page: 2833
  year: 2021
  ident: ref23
  article-title: Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
  publication-title: J. Antimicrob. Chemother.
  doi: 10.1093/jac/dkab279
– volume: 54
  start-page: 1976
  year: 2015
  ident: ref24
  article-title: Structural basis of activity against aztreonam and extended spectrum cephalosporins for two carbapenem-hydrolyzing class D β-lactamases from Acinetobacter baumannii
  publication-title: Biochemistry
  doi: 10.1021/bi501547k
– volume: 48
  start-page: 2308
  year: 2004
  ident: ref8
  article-title: High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.48.6.2308-2313.2004
– volume: 46
  start-page: 1985
  year: 2002
  ident: ref22
  article-title: CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum β-lactamase isolated from Escherichia coli
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.46.6.1985-1988.2002
– volume-title: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
  year: 2022
  ident: ref11
– volume: 29
  start-page: 159
  year: 2007
  ident: ref17
  article-title: Biochemical characterisation of the CTX-M-14 β-lactamase
  publication-title: Int. J. Antimicrob. Agents
  doi: 10.1016/j.ijantimicag.2006.09.005
– volume: 5
  start-page: 00821
  year: 2020
  ident: ref20
  article-title: Struggle to survive: the choir of target alteration, hydrolyzing enzyme, and plasmid expression as a novel aztreonam-avibactam resistance mechanism
  publication-title: mSystems
  doi: 10.1128/mSystems.00821-20
– volume: 19
  start-page: 98
  year: 2017
  ident: ref40
  article-title: Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2017.04.032
– volume: 52
  start-page: 29
  year: 2003
  ident: ref4
  article-title: Effect of D240G substitution in a novel ESBL CTX-M-27
  publication-title: J. Antimicrob. Chemother.
  doi: 10.1093/jac/dkg256
– volume: 61
  start-page: 00389
  year: 2017
  ident: ref39
  article-title: Unusual Escherichia coli PBP 3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00389-17
– volume: 10
  start-page: e0267021
  year: 2022
  ident: ref33
  article-title: Occurrence of high levels of Cefiderocol resistance in Carbapenem-resistant Escherichia coli before its approval in China: a Report from China CRE-network
  publication-title: Microbiol. Spectr.
  doi: 10.1128/spectrum.02670-21
– volume: 44
  start-page: 3061
  year: 2000
  ident: ref5
  article-title: A novel class a extended-spectrum β-lactamase (BES-1) in Serratia marcescens isolated in Brazil
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.44.11.3061-3068.2000
– volume: 55
  start-page: 390
  year: 2011
  ident: ref19
  article-title: Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00756-10
– volume: 61
  start-page: e00562
  year: 2017
  ident: ref6
  article-title: Genetic and functional characterization of blaCTX-M-199, a novel tazobactam and sulbactam resistance-encoding gene located in a conjugative mcr-1-bearing IncI2 plasmid
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00562-17
– volume: 19
  start-page: 588
  year: 2011
  ident: ref26
  article-title: The emerging NDM carbapenemases
  publication-title: Trends Microbiol.
  doi: 10.1016/j.tim.2011.09.005
– volume: 62
  start-page: 991
  year: 2008
  ident: ref9
  article-title: Natural D240G Toho-1 mutant conferring resistance to ceftazidime: biochemical characterization of CTX-M-43
  publication-title: J. Antimicrob. Chemother.
  doi: 10.1093/jac/dkn339
– volume: 8
  start-page: e56926
  year: 2013
  ident: ref15
  article-title: Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0056926
– volume: 53
  start-page: 5046
  year: 2009
  ident: ref37
  article-title: Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00774-09
SSID ssj0000402000
Score 2.376228
Snippet Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli...
Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1047109
SubjectTerms avibactam
aztreonam
CTX-M
Escherichia coli
Microbiology
resistance
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG7WFcGL-MTxRQveJNKT9CM5iOiyyyKMB9mBuYWqTo8GdpLdJCOuv8EfbVVPZjGgnrxOutOT_rq6vi_pqhLiFRQhq2hhJL6iLVBbmyeQYZ7Y1PvcQ1pY4EDhxSd7utQfV2Z1IPbljsYJ7P8o7bie1LI7f_P98uodGfxbVpzkbwmB2iNJvTTlL5Z8uPCGuEmeybGhLka6H3dmFktK7WJn_tJ14p9iGv8J95yenPzNFZ3cFXdGDinf70C_Jw5Cc1_c2lWVvHogfn4OPbNCglMOrYQfQxeIb28S-FYj-AE2strGS0dnq2SRzI2sG0lEUF7EWCTq1q4lzULt-WVMw-KZPZyMOR2oaSb57a2kbb0DCZu6oUF8XfV8m-OeV0HNJ6glrbH6oVieHJ8dnSZj0YXEa22GxFYFYKVBpcEYszbWYYrEAotgMQTlUM8xzRGcA3JuHiCYIpjUzy0ozDRmj8Rh0zbhsZAZWO_CGuZog86oQ-qIAJGkXGe8q6qZmO-nuvRjRnIujHFekjJheMoIT8nwlCM8M_H6us_FLh_HP1t_YASvW3Iu7fhD230pR9MsFSpvUSHmOWoNUYFWLjisTEVqT8_Eyz3-Jdkef1CBJrTbvuSwJl04GnEm3GRhTEacXmnqrzGLd8HhH8o9-R9_8am4zY8dYyT1M3E4dNvwnMjSgC-iBfwCOCQWPg
  priority: 102
  providerName: Scholars Portal
Title Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli
URI https://www.proquest.com/docview/2738497202
https://pubmed.ncbi.nlm.nih.gov/PMC9674307
https://doaj.org/article/0b0c6b0bb88b44a28998d7e7bd5d2604
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-ysOBFdFUcXSWCNymmaT7aoy77gTAeZBfmVt5LM1hwOsNMR9C_Yf9o30u7y_TiXrz00CRNmt9L3u8leS9CfIAqFg0JRhYamgKNc2UGBZaZ0yGUAXTlgB2F59_c1Y35urCLg6u--EzYEB546LhPClVwqBDLEo2BZB80PnpsbENcPEUCJZ13YEylOZjNIqUGLxmywiqCqQ1I9qDWvK05nEA80EQpYP-EZU7PSB4onYun4snIFuXnoZXPxKPYnYjj4f7I38_F7fe4Y_5HwMl-LeFPv43ErFcZ_GoRQg8r2exT0tn1IptnuZVtJ4nyyU3yOqJi66XcxK4NvOzSsZnMukym6A2UtZC8TitpAt-ChFXbUSWhbXb8mfMd493yWWlJ0tS-EDcX59dnV9l4vUIWjLF95poKsDGgdLTWLq3zqJH4XhUdxqg8mhx1ieA9kBoLANFW0eqQO1BYGCxeiqNu3cVXQhbggo9LyNFFU1AB7YnqkPG4LHj-VDOR33V1HcbY43wFxs-abBCGp07w1AxPPcIzEx_vy2yGyBv_zP2FEbzPyVGz0wuSpXqUpfohWZqJ93f41zTKeOsEurje72p2YDKVpxpnwk8EY1LjNKVrf6R43RU7eij_-n808Y14zL-dvCHNqTjqt_v4lmhRj-_SCKDn5SKn59yUfwFWDA-g
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Resistance+to+aztreonam-avibactam+due+to+CTX-M-15+in+the+presence+of+penicillin-binding+protein+3+with+extra+amino+acids+in+Escherichia+coli&rft.jtitle=Frontiers+in+microbiology&rft.au=Ke+Ma&rft.au=Zhiyong+Zong&rft.au=Zhiyong+Zong&rft.au=Zhiyong+Zong&rft.date=2022-11-04&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-302X&rft.volume=13&rft_id=info:doi/10.3389%2Ffmicb.2022.1047109&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_0b0c6b0bb88b44a28998d7e7bd5d2604
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-302X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-302X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-302X&client=summon